Table 3 Estimated risk of osteoporotic fracture associated with LMWH in hemodialysis
Variables | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|---|---|---|
Baseline | ||
 Heparin Exposure LMWH (vs UFH) | 1.00 (0.72–1.39) | 1.01 (0.72–1.42) |
 Age (per year) | 1.02 (1.01–1.04) | 1.02 (1.01–1.04)** |
 Male (vs female) | 1.24 (0.94–1.65) | 1.21 (0.90–1.62) |
 Incident patients (vs prevalent) | 0.89 (0.67–1.20) | 0.84 (0.61–1.16) |
 Hospitalization in prior year | 1.11 (0.79–1.55) | 1.14 (0.77–1.70) |
Comorbidities | ||
 Cardiovascular disease | 1.14 (0.85–1.51) | 0.91 (0.65–1.28) |
 Cerebrovascular disease | 0.58 (0.30–1.09) | 0.46 (0.24–0.89)* |
 Chronic pulmonary disease | 1.30 (0.93–1.82) | 1.20 (0.84–1.71) |
 Chronic liver disease | 1.10 (0.60–2.02) | 1.25 (0.67–2.31) |
 Congestive heart failure | 1.34 (1.00–1.81) | 1.24 (0.88–1.75) |
 Diabetes | 1.20 (0.90–1.60) | 1.25 (0.92–1.72) |
 Hyperlipidemia | 1.22 (0.90–1.66) | 1.16 (0.82–1.65) |
 Hypertension | 0.96 (0.69–1.34) | 0.75 (0.51–1.11) |
 Malignancy | 1.53 (1.10–2.12) | 1.50 (1.07–2.10)* |
 Peripheral vascular disease | 1.29 (0.95–1.75) | 1.29 (0.92–1.81) |
 Rheumatoid arthritis | 1.73 (0.71–4.21) | 1.51 (0.61–3.75) |
 Osteoporosis | 1.48 (0.87–2.51) | 1.20 (0.69–2.09) |
 Prior fracture | 1.57 (0.77–3.18) | 1.33 (0.64–2.76) |
Drug use 6 months prior | ||
 NSAID | 1.03 (0.77–1.37) | 0.87 (0.63–1.20) |
 Steroids | 1.04 (0.70–1.54) | 0.97 (0.64–1.46) |
 Calcium | 1.04 (0.77–1.41) | 1.07 (0.62–1.85) |
 Vitamin D | 1.32 (0.99–1.77) | 1.37 (0.98–1.92) |
 Phosphorus chelating agents | 0.96 (0.70–1.30) | 0.71 (0.41–1.26) |
 Cinacalcet | 0.53 (0.07–3.80) | 0.62 (0.09–4.47) |